Clik here to view.
Takeda Reports Third Quarter FY2018 Results
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): Underlying Revenue +4.8% year-to-date with growth of prescription drug portfolio in all regions Solid Underlying Revenue...
View ArticleClik here to view.
Samsung Bioepis and C-Bridge Capital to Develop and Commercialize...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced its expansion in mainland China through a licensing agreement with C-Bridge Capital. The agreement covers multiple biosimilar candidates from...
View ArticleClik here to view.
European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the...
CAMBRIDGE, Mass. and OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) extended the current marketing authorization of ADCETRIS...
View ArticleClik here to view.
Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved...
NEW YORK & TOKYO Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today results from the Phase 3 ARCHES trial in men...
View ArticleClik here to view.
武田公布2018财年第三季度业绩
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO:4502, NYSE:TAK)： 本年至今基础营收增长+4.8%，处方药产品组合在各个地区均有增长 基础营收稳步增长+4.8%，武田的增长引擎（胃肠药、肿瘤药、神经科药物和新兴市场）维持了强劲势头 ，增长+10.5%。 主要增长产品Entyvio...
View ArticleClik here to view.
Samsung Bioepis与C-Bridge Capital联手在中国开展下一代生物类似物的开发和商业化
韩国仁川 (美国商业资讯) — Samsung Bioepis Co., Ltd.今天宣布，通过与C-Bridge Capital的一份授权协议在中国大陆扩大经营。该协议涵盖来自Samsung Bioepis的多个候选生物类似物，包括第三波候选生物类似物SB11和SB12，商品名分别为LUCENTIS® (ranibizumab)和SOLIRIS®...
View ArticleClik here to view.
欧盟委员会核准ADCETRIS® (brentuximab vedotin)联合AVD用于既往未曾治疗的CD30+...
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(Takeda Pharmaceutical Company Limited)(TSE:4502/NYSE:TAK)今天宣布，欧盟委员会(EC)扩大了ADCETRIS (brentuximab vedotin)现有的上市许可，纳入联合AVD（阿霉素、长春碱、达卡巴嗪）治疗既往未曾治疗的CD30+...
View ArticleClik here to view.
欧州委員会、未治療のCD30陽性ステージ4ホジキンリンパ腫成人患者に対する数十年ぶりの新規治療法となるアドセトリス（ブレンツキシマブ・ベドチン）とAVDの...
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Minomic与美国病理实验室签署协议
悉尼 前列腺癌症诊断公司Minomic International Ltd荣幸地宣布：公司已经和美国临床实验室改进法案修正案（CLIA）认证的“高端复杂性”实验室Cirrus Dx正式签署协议。借此，美国的临床医生和病患届时将可受惠于Minomic公司的新型前列腺癌检测技术MiCheck®。根据协议，等到内部验证流程完毕，Cirrus Dx就可以把MiCheck®...
View ArticleClik here to view.
Shinkowa Pharmaceutical Co., Ltd. Receives an Interim Report of Clinical...
TOKYO Shinkowa Pharmaceutical Co., Ltd. (main office: Chuo-ku, Tokyo, Japan; CEO: Megumi Tanaka) has confirmed for the first time in the world, thanks to the interim report of clinical research on...
View ArticleClik here to view.
Owlstone Medical 与上海交通大学医学院附属仁济医院 率先在中国进行肺癌呼吸活检临床测试
英国剑桥和中国上海同步发布 Owlstone Medical 有限公司是全球医疗诊断公司，开发用于早期疾病检测和精准医学应用的呼气活检器。 Owlstone Medical 与上海交通大学医学院附属仁济医院（下称仁济医院），今日宣布在中国 联合开展肺癌早期检测的临床试验，项目获得李嘉诚基金会的支持。 有见肺癌在中国的病发率不断上升，Owlstone...
View ArticleClik here to view.
Owlstone Medical Partners with Shanghai Renji Hospital to Pioneer Breath...
CAMBRIDGE, England & SHANGHAI, China Owlstone Medical Ltd., a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, and Renji...
View ArticleClik here to view.
CHA Health Systems Subsidiary to Form the Largest Healthcare Network to...
LOS ANGELES CHA Health Systems (CHS), a global leader in bio-technology and healthcare, announced that its international subsidiary, CHA Healthcare Singapore Pte. Ltd. (CSG), became the largest...
View ArticleClik here to view.
Furukawa Electric Launches Single Cell Hunter for Functional Identification...
TOKYO Furukawa Electric (TOKYO:5801)(ISIN:JP3827200001) announced the launch of the Single Cell Hunter, a microchip-based automated live cell high-throughput screening system today. The breakthrough...
View ArticleClik here to view.
March is Lymphedema Awareness Month: ImpediMed Kicks Off Support on World...
BRISBANE, Australia & CARLSBAD, Calif. ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status...
View ArticleClik here to view.
Vedolizumab (Entyvio®) Achieves Superior Rates of Clinical Remission vs....
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the Phase 3b head-to-head VARSITY study which demonstrated that the gut-selective...
View ArticleClik here to view.
Results by Genetron on Early-Stage Liver Cancer Detection in At-Risk...
BEIJING Today, Proceedings of the National Academy of Sciences (PNAS) published the results of a pilot study for early detection of liver cancer in a cohort of HBV carriers, who are at risk for...
View ArticleClik here to view.
オンコイミュニティー、機械学習を使用した新生抗原予測技術の臨床使用に対しCE-IVDマークを取得した初の企業に
ノルウェー・オスロ （ビジネスワイヤ） — オンコイミュニティーは、機械学習を使用した新生抗原予測技術の臨床使用に対しCE-IVDマークを取得した初の企業になりました。今回の品質保証認定は、個別化がんワクチン／細胞療法のデザインへの新生抗原予測技術の使用の水準を高める上で重要な前進となります。...
View ArticleClik here to view.
Kyowa Kirin Asia Pacific Announces Establishment of Subsidiary in Australia
TOKYO Kyowa Kirin Asia Pacific Pte. Ltd. (President: Chikakuni Kotani, Kyowa Kirin Asia Pacific), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (President & COO: Masashi Miyamoto,...
View ArticleClik here to view.
Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives...
LOS ANGELES Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing authorization from Australia’s Therapeutic Goods...
View Article